Interview Dr Rafael Rosell

Our Research

Personalized medicine in cancer

The term cancer refers not to a single disease, but to a group of diseases with different prognoses and treatments. Thanks to advances in understanding of cancer molecular biology, we now know that genetic alterations drive the growth of a tumor and that targeting these alterations with specific drugs can, in certain cases, give better results. Investigations in the field have led to the identification of “genetic fingerprints” (biomarkers) for cancerous cells which predict sensitivity or resistance to a given drug.
Therefore, doctors are able to select the most appropriate treatment for the patient based on this genetic information.

Biomarker discovery

MORe funds research in therapeutic oncology based on personalized models. The aim is to identify predictive gene signatures and help to bring to market new, effective targeted drugs which can help doctors take therapeutics decisions and maximize the potential treatment benefit for the patient. The goal is to achieve personalized treatments based on the genetic characteristics of the disease.

This unique approach has already generated solid predictive signatures in the field of lung cancer, breast cancer and bladder cancer.

Translational research

We fund development and promotion of translational research projects in the field of oncology. We fund research in the laboratory in all types of cancers which can rapidly and safely be put used by doctors in the treatment of patients.


New analytic tools to apply personalized medicine by means of large-scale screening using next-generation screening (NGS) and whole genome sequencing (WGS) techniques.
New strategies of bio-informatic analysis to interpret NGS & WGS screening results and stratify treatment in cancer patients, using both clinical information and multiple biomarkers
  • DNA alterations
  • RNA expression
  • Protein expression
  • Gene promoter hypermethylation
In vitro platforms using cell lines to test new drugs and seek for new combinations to accelerate drug development.